Treatment of Castrate (Hormone) Resistant Stage 4 Prostate Cancer
Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008. The clinical behavior of prostate cancer ranges from a microscopic, well-differentiated tumor to an aggressive cancer with high likelihood of invasion and metastasis (spread to other organs).
Prostate cancer has increased in frequency, due in part to the widespread availability of serum prostate specific antigen (PSA) testing. The incidence peaked in 1992, declined between 1992 and 1995, and has been rising about 1 percent annually since then. The reasons for the increasing incidence are not known.
Since the introduction of widespread screening using serum PSA, prostate cancer is often diagnosed while asymptomatic. However, screening with serum PSA is controversial, since many of the prostate cancers discovered in this manner may never be clinically significant.
A prostate biopsy is indicated in men with a digital rectal examination that is suspicious for cancer, even if the serum PSA is normal. Transrectal ultrasonography (TRUS) is often used to evaluate abnormalities detected by digital rectal examination and to guide sites for prostate biopsy
There is significant overlap in the serum PSA values that accompany prostate cancer and benign prostatic hypertrophy, but the likelihood of finding cancer on a prostate biopsy increases with higher PSA values. In one series, the positive predictive value for detecting prostate cancer on prostate biopsy with serum PSA levels 4 to 10 ng/mL and >10 ng/mL were 21 to 22, and 42 to 64 percent, respectively.
Here, Dr. Tony Talebi discusses the treatment of castrate resistant stage 4 prostate cancer with Dr. Rakesh Singal, associate professor of oncology at the University of Miami and a world renowned figure in genitourinary cancers. The discussion includes symptoms, staging, genetic implications, diagnosis, PSA values, surgery, radiation therapy, hormonal therapy and chemotherapy for prostate cancer,prostate cancerprognosis, what causesprostate
cancer, signs ofprostate
cancer, prostate cancersymptoms, prostate cancer, prostate
cancerstage
4, treatment ofprostate cancer, prostate cancerassociation, stage fourprostate
cancer, small cellprostate
cancer, symtoms ofprostate
cancer, causes ofprostate
cancer, prostate cancerchemotherapy, what isprostate cancer, prostate cancers, prostate cancerinformation, prostate cancerprevention, stage 4prostate
cancer, information aboutprostate
cancer, stage ivprostate
cancer, prostate cancersigns, prostate cancersymptom, isprostate
cancercurable,
stage 3bprostate cancer, lungs cancer symptoms, survival rates forprostate
cancer, symptoms ofprostate
cancer, prostate cancersurvivors, prostate cancersymptons, prostate cancersurvival, treatments ofprostate
cancer, symptons ofprostate
cancer, prostate cancerstatistics, non small cellprostate
cancer, chemo forprostate
cancer, prostate cancersurvival rate, large cellprostate cancer, effects ofprostate
cancer, prostate cancerscreening, prostate cancerdiagnosis, prostate cancersociety, prostate cancerclinical trials, prostate cancermetastasis, survival rateprostate
cancer, symptom ofprostate
cancer, info onprostate
cancer, new treatments forprostate
cancer, how common isprostate
cancer.
Dr. Rakesh Singal credentials:
Certifications
American Board of Internal Medicine
American Board of Internal Med-Hematology
American Board of Internal Med-Medical Oncology
Specialties
Hematology/Oncology - Internal Medicine
Internal Medicine
Roles
Associate Professor of Medicine
Clinical Interests
Genitourinary maliganancies, prostate cancer, bladder cancer
Research Interests
Prostate cancer, epigenetics, transcriptional regulation, DNA methylation, chromatin structure, biomarkers